UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 15, 2012

BioDrain Medical, Inc.

(Exact name of Registrant as Specified in its Charter)

Minnesota

(State or Other Jurisdiction of Incorporation)

333-155299 (Commission File Number) 33-1007393

(IRS Employer Identification No.)

2915 Commers Drive, Suite 900 Eagan, Minnesota 55121

(Address of Principal Executive Offices and Zip Code)

(651) 389-4800 (651) 389-4800

(Registrant's telephone number, including area code)

2060 Centre Pointe Boulevard, Suite 7 Mendota Heights, Minnesota 55120

(Former Address)

Check to	he appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following ons:
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors	; Appointment of Certain Officers; C	ompensatory Arrangements of Certain
Officers.		

(a) Departure of Officer or Director

Effective May 14, 2012, Kevin Davidson resigned as a member of the Registrant Board of Directors.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 15, 2012

BIODRAIN MEDICAL, INC.

By: /s/ Joshua Komberg Joshua Komberg Chief Executive Officer,